William (Bill) has more than 23 years of experience in the pharmaceutical industry. Prior to joining Custopharm, Bill was vice president and general manager of Bedford Laboratories, Inc., where he oversaw a portfolio of more than 100 registered generic injectable products. Previously, he was senior director of product development at Amylin Pharmaceuticals Inc., where he managed development activities for proprietary peptide and protein injectable products. Bill also held positions at Novartis, ESI-Lederle, Barr Laboratories, Inc. and Schein Pharmaceutical, Inc. He began his career as an analytical research chemist. Bill received a doctorate degree in analytical chemistry from The Ohio State University and a bachelor’s degree in chemistry from Purdue University.
sterile injectable generic
Solving formulation and
Writing and publishing
We are Growing.
Founded in 2005, Custopharm has steadily grown to develop more than 30 products
and serve more than 100 organizations across the pharmaceutical industry. In 2015
we partnered with Water Street Healthcare Partners, a strategic investor with extensive
pharmaceutical expertise, to accelerate Custopharm's growth. Since then, we have
enhanced our Regulatory Services team to better support our partners, and augmented
our scientific team to develop more complex pharmaceutical products. With many new
products in development and new opportunities on the horizon, we expect to double
in size and commercialize our own products within the next year.
Our goal is to become a US leader in
generic injectable products. Together with
Water Street, we are investing heavily to expand
our operations, enhance our scientific
personnel, and to pursue new partnerships and
product acquisitions. We are confident that
Custopharm will dramatically increase its role in
bringing important new generic injectable
products to market.
Custopharm has assembled a highly experienced team of
industry executives to lead and grow our company. Our executive
team has deep expertise in sterile injectable pharmaceutical
products and a strong track record of success.
William Larkins, PhD, Chief Executive Officer
Jeff Keyes, Chief Financial Officer
Jeff is responsible for overall financial operations, information technology, and human resources. He brings over 20 years of relevant experience, including significant experience in the public and private healthcare and life sciences companies. His most recent experience includes work for medical device and biotechnology companies, encompassing IPO readiness, M&A and significant restructuring activities. Prior to joining Custopharm, Jeff was the Chief Financial Officer of Digirad, a publicly traded healthcare services and medical device company, where he helped grow revenues over $75 million annually through a series of acquisitions and restructuring. Prior to this, Jeff held senior financial roles at Sapphire Energy, Advanced BioHealing (sold to Shire for $750 million) and CareFusion (sold to Becton Dickinson). Jeff holds a bachelor’s degree in accounting and economics, and is a Certified Public Accountant in the state of Washington.
Mohammad Ali, VP of Technology Transfer and Manufacturing
Mohammad has more than (25) years of experience in the pharmaceutical industry. Prior to joining Custopharm, Mohammad has successfully managed manufacturing, engineering and technology transfer functions in regulated cGMP environments most recently with West Ward Pharmaceuticals. He has extensive knowledge and experience in process development and manufacturing of small and large molecule parenteral products, including biologics, nanoparticle suspensions, emulsions, liposome, liquid and lyophilized dosage forms packaged in vials, syringe, cartridges and bags. Mohammad in past has held positions with increasing responsibilities at Ben Venue Labs, Baxter Biopharma Solutions, American Pharmaceutical Partners and DOW Chemical Co. Mohammad received his Master’s degree in Industrial Engineering from University of Cincinnati and Bachelor’s degree in Mechanical Engineering from NED University of Engineering.
Michael Davidson, VP of Business Development and Licensing
Michael has more than 23 years of progressively increasing level of responsibilities working in the areas of Operations, Project Management, Strategic Sourcing, and Business Development & Licensing, while serving both the Branded and Generic sectors of the Pharmaceutical Industry. He is passionate about canvassing and exploring the global pharmaceutical landscape to identify and develop new strategic partnerships to bring affordable medicines into Custopharm’s portfolio to help serve and address the unmet needs of a growing and aging patient population. Mike has successfully designed, built and led numerous cross-functional and global teams to the highest level of performance within several top 20 Global Pharmaceutical Companies Worldwide during the course of his work tenure. Among his most recent previous positions, Mike served as Senior Director, Alliance Management for Pfizer, Inc. and Director of Business Development and Licensing for Bedford Laboratories.
Mike holds a Bachelor of Science degree in Chemical Engineering from the University of Michigan.
We are currently recruiting for a number of career opportunities, including: analytical and formulation scientists, project managers, regulatory associates, financial analysts, and laboratory and office assistants. If you are interested in becoming part of an entrepreneurial, growing organization, please click here to review our positions and submit your resume.
Custopharm is actively pursuing new product and partnership opportunities.
We are looking to acquire sterile injectable products, strategically partner with
development and manufacturing companies, and provide enhanced support
for our regulatory services partners.
If you are interested in opportunities to partner with Custopharm,
please click here to submit your contact information.